Labcorp Holdings Inc. (LH) Stock: Price, Forecast & Analyst Target
Labcorp Holdings Inc. (LH) — MoonshotScore 71/100 (Strong band), calculated Nov 18, 2026. Price $370.78 (+0.69%), as of the Nov 18, 2026 trading session; market cap $30.1B. Expected results Feb 16, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Labcorp Holdings Inc. · LH · NYSE · Healthcare · Medical - Diagnostics & Research
Research dated 2026-09-12: Labcorp sells diagnostic and research laboratory services to clinicians, healthcare facilities, drug developers, investigators, and patients; it is not merely a manufacturer of laboratory tests. The case rests on whether rising laboratory demand and improving profit conversion can outweigh heavy debt and the sharp contraction in readily available cash.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · Labcorp Holdings (LH)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, though the balance sheet and growth are only middling; the market is already moving on it. Business Quality: Solid; Financial Safety: Okay; Valuation: Fair; Growth Durability: Flat; Momentum: Surging.
- EPS beat 0 of the last 4 reports
- expected results Feb 16, 2027
- Altman Z 3.54 · Piotroski F 8
Helping: business quality, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 73 | Strong | |
| 73 | Strong | |
| 73 | Strong | |
| 73 | Strong | |
| 71 | Strong | |
| 71 | Strong |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $370.78 | |
| Change on the day | +0.69% | |
| 52-week range | $245.00–$375.10 | |
| Market capitalisation | $30.1B | — |
| Price / earnings (trailing) | 30.01 | |
| Shares traded on the day | 689.9K | |
| Beta (volatility vs the S&P 500) | 0.84 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Labcorp Holdings (LH): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 17, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Labcorp Holdings (LH), and what does it report?
Short answer · as of
Labcorp processes clinical testing for patient care while also providing laboratory services used in pharmaceutical research and development.
Research dated 2026-09-12.
Demand therefore comes from medical testing activity and drug-development programs, making the company broader than its diagnostics classification suggests.
Companywide revenue combines activities with different demand drivers. Lab Corp Diagnostics accounts for most disclosed segment revenue, while management separately discusses Central Labs and Early Development, so the consolidated result is not a pure measure of routine patient testing.
What do the latest results show for Labcorp Holdings (LH)?
Research dated 2026-09-12.
The latest period extended revenue growth and produced stronger gross profit, operating profit, net income, and diluted earnings than the preceding period. Revenue and adjusted earnings also cleared market estimates, continuing a pattern in which adjusted earnings have exceeded expectations even when revenue occasionally missed.
Management maintained its free-cash-flow outlook and still expects Central Labs to grow faster than Early Development. That distinction matters: the reported improvement is visible in the financial statements, while the expected growth mix remains management guidance rather than an accomplished result.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $3.56B | $261M | $3.12 (diluted) |
| Q4 FY2025 | $3.52B | $165M | $1.98 (diluted) |
| Q1 FY2026 | $3.54B | $278M | $3.35 (diluted) |
| Q2 FY2026 | $3.73B | $299M | $3.64 (diluted) |
What are the financial strengths and risks for Labcorp Holdings (LH)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12.
Labcorp remains profitable and has generated positive operating cash flow throughout the reported sequence, although conversion is uneven and recurring capital expenditure absorbs part of that cash. Liquidity ratios remain above parity, and the quality and distress screens are favorable.
The balance sheet carries substantial debt against a much smaller pool of cash and investments. Readily available cash has fallen sharply across the reported window, leaving operating cash generation more important to financial flexibility; the unchanged dividend also represents a continuing call on capital.
A slowdown in diagnostic activity or pharmaceutical laboratory work would pressure earnings while debt obligations and capital spending remain. That combination makes sustained cash conversion more consequential than an isolated earnings beat.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
- Rich valuation — a P/E of 30.01 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
What should you watch next at Labcorp Holdings (LH)?
Short answer · as of
The next earnings report is expected on Feb 16, 2027.
Research dated 2026-09-12.
The upcoming earnings release should be read across revenue, gross profit, operating profit, and operating cash flow. Consensus implies modest sequential revenue progress but lower adjusted earnings than the latest reported comparison, so the quality of growth matters as much as clearing the headline estimates.
Watch whether cash rebuilds after its abrupt decline and whether operating cash flow covers capital expenditure with enough room to support debt and shareholder distributions. Progress in Central Labs alongside slower Early Development would align with management's stated mix; weakness across those laboratory activities would challenge it.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
Checked against the records this page reads, on the dates shown above.
How does Labcorp Holdings compare with its peers?
Short answer
Labcorp Holdings's score ranks tied for 10th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Labcorp combines high-volume diagnostic services with laboratory work tied to pharmaceutical development. That gives it exposure to patient testing and research programs within the same company, unlike a business concentrated solely in routine clinical diagnostics or solely in outsourced drug-development work.
The trade-off is financial rather than merely operational: this breadth sits alongside meaningful leverage and limited cash relative to debt. Comparisons with similar laboratory businesses therefore need to account for service mix, cash conversion, and financing demands together.
| Company | Price | Market value | Score |
|---|---|---|---|
| $577.34 Nov 18, 2026 | $24.6B | 97 5-pillar Nov 18, 2026 | |
| $698.47 Nov 18, 2026 | $55.0B | 96 5-pillar Nov 18, 2026 | |
| $82.52 Nov 18, 2026 | $30.8B | 93 5-pillar Nov 18, 2026 | |
| $1737.26 Nov 18, 2026 | $34.6B | 93 5-pillar Nov 18, 2026 | |
| $646.87 Nov 18, 2026 | $18.1B | 92 5-pillar Nov 18, 2026 | |
| $259.57 Nov 18, 2026 | $25.2B | 87 5-pillar Nov 18, 2026 | |
| $210.01 Nov 18, 2026 | $31.8B | 84 5-pillar Nov 18, 2026 | |
| $177.33 Nov 18, 2026 | $50.0B | 83 5-pillar Nov 18, 2026 | |
| $259.52 Nov 18, 2026 | $28.6B | 74 5-pillar Nov 18, 2026 | |
| Labcorp Holdings (LH) — this page | $370.78 | $30.1B | 71 |
| $257.84 Nov 18, 2026 | $42.5B | 71 5-pillar Nov 18, 2026 | |
| $152.43 Nov 18, 2026 | $17.0B | 71 5-pillar Nov 18, 2026 | |
| $333.25 Nov 18, 2026 | $16.0B | 70 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $355.00 – $420.00
- Consensus target
- $389.89
- Median target
- $395.00
Consensus record · Captured .
Measured against a quoted price of $370.78 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 10, 2026
- Transactions
- 29
- Identified insiders
- 10
- Purchases
- 0
- Sales
- 11
- Other transactions
- 18
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held LH in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported LH in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Labcorp Holdings (LH)?
Common Questions About LH (Healthcare)
Research dated 2026-09-12; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
How does Labcorp make money from diagnostics and drug development?
Labcorp earns revenue by providing laboratory services for medical decision-making and for pharmaceutical research. Routine diagnostic activity and drug-development programs therefore feed different parts of the same operating platform.
Why can Labcorp revenue rise while its cash balance falls?
Revenue and accounting profit have increased, but cash also moves with operating conversion, capital expenditure, financing, distributions, and other uses. Recent operating cash flow remained positive while readily available cash contracted sharply, so earnings growth has not translated into cash accumulation.
What matters in Labcorp's Central Labs and Early Development outlook?
Management expects Central Labs to expand faster than Early Development. The relative performance of those activities will indicate whether growth is broad across pharmaceutical laboratory services or concentrated in the stronger operation.
What do Labcorp insider filings show about awards and sales?
Recent activity included sales and transactions classified as awards, in-kind movements, and exempt exercises, with no reported purchases. Those records describe transaction types but do not establish why an insider sold or received shares.
What is the LH stock price today?
The last price recorded for Labcorp Holdings Inc. (LH), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the LH price target?
The analyst consensus price target for Labcorp Holdings Inc. (LH), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 24 figures on this page — 1 from SEC filings and earnings calls, 19 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-12), by section of the research
ETFs that hold LH
Funds in our ETF coverage that list LH among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| IHF ETF | 4.05% | |
| Allspring Special Large Value ETF (ASLV) | 3.08% |